Physician profile
Jonathan Lovy
NPI 1598777047
$6,460.83
in general payments reported to CMS, 2019-2025
38 companies · $330 in 2025
The $330 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $970 · 2020: $894 · 2021: $1,383 · 2022: $1,307 · 2023: $961 · 2024: $616 · 2025: $330.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,113.75 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $705.78 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $588.08 | 2019-2025 | |
| Abbvie INC. | $552.25 | 2021-2024 | |
| Astellas Pharma US INC | $393.81 | 2019-2025 | Veozah, Myrbetriq |
| Astrazeneca Pharmaceuticals Lp | $308.28 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $306.19 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $265.49 | 2019-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $265.48 | 2019-2023 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $242.11 | 2019-2024 | Eliquis |
| Lilly USA, LLC | $216.40 | 2019-2025 | Mounjaro, Zepbound |
| Xeris Pharmaceuticals, INC. | $190.88 | 2022-2023 | Gvoke Hypopen |
| Teva Pharmaceuticals USA, INC. | $168.22 | 2019-2024 | Austedo Xr, Ajovy |
| Novartis Pharmaceuticals Corporation | $142.77 | 2019-2024 | |
| Biogen, INC. | $118.06 | 2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $108.16 | 2019-2022 | |
| Boston Scientific Corporation | $85.01 | 2023-2024 | Watchman Flx, Watchman Access System |
| Eisai INC. | $71.70 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $55.33 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $55.25 | 2021 | |
| Uswm, LLC | $50.94 | 2023 | Zimhi, Lucemyra |
| Amgen INC. | $50.89 | 2023-2024 | Repatha, Otezla, Krystexxa |
| Horizon Therapeutics Plc | $46.73 | 2021-2022 | |
| Amarin Pharma, INC. | $41.71 | 2020 | |
| Abbott Laboratories | $39.40 | 2021-2023 | Freestyle Libre 3 |
| Vanda Pharmaceuticals INC. | $35.67 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $31.96 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.36 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $24.54 | 2021 | |
| Grt US Holding, INC. | $23.32 | 2022 | |
| Dexcom, INC. | $21.64 | 2021 | |
| Smith+Nephew, INC. | $19.65 | 2019 | |
| Avanir Pharmaceuticals, INC. | $17.10 | 2019 | |
| Corcept Therapeutics | $16.30 | 2024 | Korlym |
| Mdd US Operations, LLC | $16.04 | 2019 | |
| Exact Sciences Corporation | $15.16 | 2023 | Cologuard Collection Kit |
| Allergan, INC. | $12.71 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $12.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Lovy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.